Organogenesis Holdings (NASDAQ:ORGO) expects Q2 net revenue between $68M – $68.6M vs. consensus of $48.25M and net revenue from PuraPly products between $27.7M – $28.1M, down 5% to 7% Y/Y.
Advanced Wound Care revenue between $59.7M and $60.1M.
Surgical & Sports Medicine revenue between $8.3M and $8.5M.
Q2 results will be out after the market closes on August 10, 2020.
Shares up 29.8% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.